{"id":22130,"date":"2024-01-23T08:00:00","date_gmt":"2024-01-23T07:00:00","guid":{"rendered":"https:\/\/ggba.swiss\/cellestia-biotech-receives-chf-2-million-for-its-pioneering-gvhd-prevention-therapy\/"},"modified":"2024-01-23T09:49:07","modified_gmt":"2024-01-23T08:49:07","slug":"cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/","title":{"rendered":"Cellestia Biotech re\u00e7oit CHF 2 millions pour sa th\u00e9rapie de pr\u00e9vention de la GvHD"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.cellestia.com\/\">Cellestia<\/a>, une biotech lausannoise sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de nouvelles th\u00e9rapies pour les maladies auto-immunes et les cancers multir\u00e9sistants, a re\u00e7u une bourse de CHF 2 millions de la part d&rsquo;<a href=\"https:\/\/www.innosuisse.ch\/inno\/fr\/home.html\">Innosuisse<\/a>, l&rsquo;agence suisse pour l&rsquo;innovation. Cette bourse, qui s&rsquo;inscrit dans le cadre du projet Startup Innovation, vise \u00e0 faire progresser le CB-103, un m\u00e9dicament de premi\u00e8re classe pour la pr\u00e9vention de la maladie du greffon contre l&rsquo;h\u00f4te (GvHD), jusqu&rsquo;\u00e0 la preuve de concept clinique.<\/p>\n\n\n\n<p>Aujourd&rsquo;hui bas\u00e9e sur le campus des sciences de la vie du <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le<\/a> \u00e0 Lausanne, Cellestia a \u00e9t\u00e9 fond\u00e9e en tant que spin-off de l&rsquo;Institut Suisse de Recherche Exp\u00e9rimentale sur le Cancer (<a href=\"https:\/\/www.isrec.ch\/accueil\">ISREC<\/a>) de l&rsquo;EPFL.&nbsp; La mol\u00e9cule phare de l&rsquo;entreprise, CB-103, cible sp\u00e9cifiquement le complexe de transcription CSL-NOTCH et s&rsquo;est r\u00e9v\u00e9l\u00e9e prometteuse en termes d&rsquo;innocuit\u00e9 et d&rsquo;activit\u00e9 biologique lors d&rsquo;essais sur l&rsquo;homme.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un impact significatif dans un domaine m\u00e9dical d\u00e9licat<\/h4>\n\n\n\n<p>Le projet de Cellestia porte sur le d\u00e9veloppement du CB-103 en tant qu&rsquo;approche innovante pour pr\u00e9venir la GvHD chez les patients subissant une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (HSCT). \u00ab&nbsp;Nous remercions sinc\u00e8rement Innosuisse d&rsquo;avoir reconnu le potentiel du CB-103 pour am\u00e9liorer la vie des patients aux prises avec la GvHD&nbsp;\u00bb, a d\u00e9clar\u00e9 Raj Lehal, CEO de Cellestia.<\/p>\n\n\n\n<p>La GvHD reste la principale cause de mortalit\u00e9 non li\u00e9e \u00e0 une rechute chez les personnes ayant subi une allogreffe de moelle osseuse, affectant plus de 50% des patients. La norme actuelle de soins pour la pr\u00e9vention de la GvHD est insuffisante, ce qui entra\u00eene des taux de mortalit\u00e9 \u00e9lev\u00e9s. Gr\u00e2ce \u00e0 l&rsquo;approche innovante de Cellestia, il est possible d&rsquo;avoir un impact significatif dans ce domaine m\u00e9dical d\u00e9licat.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.<\/p>\n","protected":false},"author":6,"featured_media":22126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1140,1141],"class_list":["post-22130","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-oncology-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cellestia re\u00e7oit CHF 2M pour sa th\u00e9rapie de pr\u00e9vention de la GvHD<\/title>\n<meta name=\"description\" content=\"La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellestia re\u00e7oit CHF 2M pour sa th\u00e9rapie de pr\u00e9vention de la GvHD\" \/>\n<meta property=\"og:description\" content=\"La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-23T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-23T08:49:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Cellestia Biotech re\u00e7oit CHF 2 millions pour sa th\u00e9rapie de pr\u00e9vention de la GvHD\",\"datePublished\":\"2024-01-23T07:00:00+00:00\",\"dateModified\":\"2024-01-23T08:49:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\"},\"wordCount\":336,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Oncology\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\",\"name\":\"Cellestia re\u00e7oit CHF 2M pour sa th\u00e9rapie de pr\u00e9vention de la GvHD\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png\",\"datePublished\":\"2024-01-23T07:00:00+00:00\",\"dateModified\":\"2024-01-23T08:49:07+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Cellestia Biotech est \u00e0 l'origine de traitements innovants bas\u00e9s sur de nouveaux modes d'action pour traiter les maladies auto-immunes et les cancers multir\u00e9sistants. | \u00a9 Cellestia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellestia Biotech re\u00e7oit CHF 2 millions pour sa th\u00e9rapie de pr\u00e9vention de la GvHD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellestia re\u00e7oit CHF 2M pour sa th\u00e9rapie de pr\u00e9vention de la GvHD","description":"La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/","og_locale":"fr_FR","og_type":"article","og_title":"Cellestia re\u00e7oit CHF 2M pour sa th\u00e9rapie de pr\u00e9vention de la GvHD","og_description":"La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.","og_url":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-01-23T07:00:00+00:00","article_modified_time":"2024-01-23T08:49:07+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Cellestia Biotech re\u00e7oit CHF 2 millions pour sa th\u00e9rapie de pr\u00e9vention de la GvHD","datePublished":"2024-01-23T07:00:00+00:00","dateModified":"2024-01-23T08:49:07+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/"},"wordCount":336,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png","keywords":["Biotech","Financing","Oncology","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/","url":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/","name":"Cellestia re\u00e7oit CHF 2M pour sa th\u00e9rapie de pr\u00e9vention de la GvHD","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png","datePublished":"2024-01-23T07:00:00+00:00","dateModified":"2024-01-23T08:49:07+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La biotech Cellestia, bas\u00e9e au Biop\u00f4le, a re\u00e7u une bourse Innosuisse de CHF 2 millions pour sa nouvelle th\u00e9rapie de pr\u00e9vention de la GvHD.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Cellestia-Team-1180x811-1.png","width":1180,"height":811,"caption":"Cellestia Biotech est \u00e0 l'origine de traitements innovants bas\u00e9s sur de nouveaux modes d'action pour traiter les maladies auto-immunes et les cancers multir\u00e9sistants. | \u00a9 Cellestia"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/cellestia-biotech-recoit-chf-2-millions-pour-sa-therapie-de-prevention-de-la-gvhd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Cellestia Biotech re\u00e7oit CHF 2 millions pour sa th\u00e9rapie de pr\u00e9vention de la GvHD"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=22130"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22130\/revisions"}],"predecessor-version":[{"id":22132,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22130\/revisions\/22132"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/22126"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=22130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=22130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=22130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}